Genmab A/S (GNMSF) Net Income (2018 - 2026)
Genmab A's (GNMSF) quarterly Net Income came in at -$106.0 million in Q1 2026, down 143.44% YoY from $244.0 million in Q1 2025, and down 109.23% on a QoQ basis from $1.1 billion in Q3 2025.
Genmab A/S (GNMSF) Net Income (2018 - 2026) Analysis & Trends
Genmab A (GNMSF) has 6 years of Net Income data on file, last reported at -$106.0 million in Q1 2026.
- Quarterly Net Income fell 143.44% year-over-year to -$106.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.6 billion (up 8.7% YoY) and the FY2025 annual result came in at $963.0 million, down 15.0% from the prior year.
- Net Income retreated to -$106.0 million in Q1 2026, from $1.1 billion in the prior quarter.
- In the past five years, Net Income ranged from a high of $1.1 billion in Q3 2025 to a low of -$106.0 million in Q1 2026.
- A 3-year average of $467.3 million and a median of $395.0 million in 2024 frame the typical range for Net Income.
- Annual changes were most pronounced in 2025 — Net Income jumped 42.03% — and 2026, when it plunged 143.44%.
- Tracing GNMSF's Net Income over 3 years: stood at $809.0 million in 2024, then soared by 42.03% to $1.1 billion in 2025, then sank by 109.23% to -$106.0 million in 2026.
- The last three Net Income figures came in at -$106.0 million (Q1 2026), $1.1 billion (Q3 2025), and $531.0 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 303.00 Mn |
| Mar 31, 2026 | -106.00 Mn |
| Sep 30, 2025 | 1.15 Bn |
| Jun 30, 2025 | 531.00 Mn |
| Mar 31, 2025 | 244.00 Mn |
| Sep 30, 2024 | 809.00 Mn |
| Jun 30, 2024 | 395.00 Mn |
| Mar 31, 2024 | 249.00 Mn |
| Sep 30, 2020 | 671.00 |
| Dec 31, 2019 | 699.00 |
| Sep 30, 2019 | 699.28 Mn |
| Dec 31, 2018 | 230.60 Mn |